Relation between circulating levels of 25(OH) vitamin D and parathyroid hormone in chronic kidney disease: Quest for a threshold

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 7, 2013, Pages 2922-2928

  Metzger, Marie ^a,b   Houillier, Pascal ^c,d,e   Gauci, Cédric ^a,b,c   Haymann, Jean Philippe ^a,f,g   Flamant, Martin ^a,d,h   Thervet, Eric ^a,c,d   Boffa, Jean Jacques ^a,f,g   Vrtovsnik, François ^a,d,h   Froissart, Marc ^a,d   Stengel, Bénédicte ^a,b   Ureña Torres, Pablo ^d,i  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g SORBONNE UNIVERSITÉ   (France)

^h BICHAT HOSPITAL   (France)

ⁱ Clinique du Landy   (France)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM ION; EDETATE CHROMIUM CR 51; PARATHYROID HORMONE; PHOSPHATE;

ADULT; AGE; ARTICLE; BODY MASS; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CALCIUM URINE LEVEL; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MALE; NEGRO; OBESITY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; PHOSPHATE URINE LEVEL; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE; REFERENCE VALUE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

25-HYDROXYVITAMIN D 2; AGED; CALCIFEDIOL; CALCIUM; COHORT STUDIES; FEMALE; FRANCE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERCALCEMIA; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; VITAMIN D DEFICIENCY;

EID: 84879992198     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1294     Document Type: Article

References (40)

1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-281.
2. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998;338:777-783. (Pubitemid 28135983)
3. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997;7:439-443. (Pubitemid 27443069)
4. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005;289:F8-F28.
5. Holick MF. Vitamin D for health and in chronic kidney disease. Semin Dial. 2005;18:266-275. (Pubitemid 41159576)
6. Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ. 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int. 2006;70:654-659. (Pubitemid 44215339)
7. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81:353-373. (Pubitemid 43334631)
8. Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr. 2003;22:142-146. (Pubitemid 36417827)
9. Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med. 2004;116:634-639. (Pubitemid 38490539)
10. KDIGO. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;S1-S130.
11. Moranne O, Froissart M, Rossert J, et al for the NephroTest Study Group. Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol. 2009;20:164-171.
12. Urena-Torres P, Metzger M, Haymann JP, et al for the NephroTest Study Group. Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. Am J Kidney Dis. 2011;58:544-553.
13. Souberbielle JC, Boutten A, Carlier MC, et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int. 2006;70:345-350. (Pubitemid 44086584)
14. Krall EA, Sahyoun N, Tannenbaum S, Dallal GE, Dawson-Hughes B. Effect of vitamin D intake on seasonal variations in parathyroid hormone secretion in postmenopausal women. N Engl J Med. 1989;321:1777-1783. (Pubitemid 20015570)
15. Kruse K, Bartels H, Kracht U. Parathyroid function in different stages of vitamin D deficiency rickets. Eur J Pediatr. 1984;141:158-162. (Pubitemid 14220032)
16. Lips P, Wiersinga A, van Ginkel FC, et al. The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects. J Clin Endocrinol Metab. 1988;67:644-650.
17. Sai AJ, Walters RW, Fang X, Gallagher JC. Relationship between vitamin D, parathyroid hormone, and bone health. J Clin Endocrinol Metab. 2011;96:E436-E446.
18. Aloia JF, Talwar SA, Pollack S, Feuerman M, Yeh JK. Optimal vitamin D status and serum parathyroid hormone concentrations in African American women. Am J Clin Nutr. 2006;84:602-609. (Pubitemid 44713411)
19. Dawson-Hughes B, Harris SS, Dallal GE. Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. Am J Clin Nutr. 1997;65:67-71. (Pubitemid 27020461)
20. Ginde AA, Wolfe P, Camargo CA Jr, Schwartz RS. Defining vitamin D status by secondary hyperparathyroidism in the U.S. population. J Endocrinol Invest. 2012;35:42-48.
21. Monk RD, Bushinsky DA. Making sense of the latest advice on vitamin D therapy. J Am Soc Nephrol. 2011;22:994-998.
22. Valcour A, Blocki F, Hawkins DM, Rao SD. Effects of age and serum 25-OH-Vitamin D on serum parathyroid hormone levels. J Clin Endocrinol Metab. 2012;97:3989-3995.
23. Aloia JF, Chen DG, Chen H. The 25(OH)D/PTH threshold in black women. J Clin Endocrinol Metab. 2010;95:5069-5073.
24. González EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol. 2004;24:503-510. (Pubitemid 39656665)
25. Ishimura E, Tsuchida T. [Vitamin D deficiency/insufficiency in patients with chronic kidney disease stage 3 and 4-current concept and its therapeutic strategy]. Clin Calcium. 2004;14:764-769.
26. LaClair RE, Hellman RN, Karp SL, et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis. 2005;45:1026-1033. (Pubitemid 40806515)
27. Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005;67:760-771. (Pubitemid 40139871)
28. Melamed ML, Astor B, Michos ED, Hostetter TH, Powe NR, Muntner P. 25-hydroxyvitamin D levels, race, and the progression of kidney disease. J Am Soc Nephrol. 2009;20:2631-2639.
29. Pilz S, Henry RM, Snijder MB, et al. Vitamin D deficiency and myocardial structure and function in older men and women: the Hoorn Study. J Endocrinol Invest. 2010;33:612-617.
30. Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009;75:88-95.
31. Souberbielle JC, Body JJ, Lappe JM, et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun Rev. 2010;9:709-715.
32. Rutherford WE, Blondin J, Hruska K, Kopelman R, Klahr S, Slatopolsky E. Effect of 25-hydroxycholecalciferol on calcium absorption in chronic renal disease. Kidney Int. 1975;8:320-324.
33. Faupel-Badger JM, Diaw L, Albanes D, Virtamo J, Woodson K, Tangrea JA. Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol Biomarkers Prev. 2007;16:2784-2786. (Pubitemid 351196338)
34. Jia X, Aucott LS, McNeill G. Nutritional status and subsequent all-cause mortality in men and women aged 75 years or over living in the community. Br J Nutr. 2007;98:593-599. (Pubitemid 47272875)
35. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168:1629-1637.
36. Stolzenberg-Solomon RZ, Jacobs EJ, et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010;172:81-93.
37. Tuohimaa P, Tenkanen L, Ahonen M, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer. 2004;108:104-108. (Pubitemid 37444451)
38. Vieth R. Vitamin D toxicity, policy, and science. J Bone Miner Res 22 Suppl. 2007;2:V64-V68.
39. Visser M, Deeg DJ, Puts MT, Seidell JC, Lips P. Low serum concentrations of 25-hydroxyvitamin D in older persons and the risk of nursing home admission. Am J Clin Nutr. 2006;84:616-622; quiz 671-612.
40. Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barré M, D'Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab. 1996;81:3923-3929. (Pubitemid 26380397)